Systemic therapies, including oncology, neurology, infectious disease, and cardiovascular treatments, can carry under‑recognized risks of ocular toxicity, making proactive vision safety planning essential for protecting patients and meeting regulatory expectations. This white paper offers a clear guide for non‑ophthalmic drug developers on when ocular assessments are warranted, how to design scientifically justified protocols, and how to execute them efficiently through qualified sites, consistent imaging, and expert interpretation.
Considering Ocular Safety: Key Insights into Conducting Ophthalmic Assessments for Clinical Trials
What's inside:
Understanding Ocular Toxicities
Why common eye risks related to systemic therapies matter for clinical programs
Designing & Implementing Ocular Safety Studies
How to build and operationalize a fit‑for‑purpose monitoring strategy
Evaluating Imaging & Interpreting Results
How to ensure high‑quality assessments through expert reading and reliable data
Fill out the form below to download now:
"*" indicates required fields